Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
J Clin Med ; 12(19)2023 Sep 29.
Article in English | MEDLINE | ID: mdl-37834936

ABSTRACT

There is notable disparity between symptomatology and disease activity in a significant proportion of patients with inflammatory bowel disease (IBD), and escalation of treatment based on symptoms alone can fail to significantly alter the course of disease. The STRIDE-II position statement, published in 2021 by the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organisation for the Study of IBD (IOIBD) provides the most current recommendations for a treat-to-target (T2T) approach in IBD. Despite the benefits offered by a T2T approach in IBD, there are numerous drawbacks and current limitations to its widespread implementation in real-world clinical practice. Owing to the lack of a standardised definition of MH, outcome data are heterogeneous and limit the comparability of existing data. Further, studies investigating the likelihood of achieving MH with a T2T approach are limited and largely retrospective. Evidence of the real-world feasibility of tight monitoring is currently minimal and demonstrates sub-optimal adherence among patients. Further, the few studies on the acceptability and uptake of a T2T approach in real-world practice demonstrate the need for increased acceptability on both patients' and clinicians' behalf. Real-world applicability is further limited by the need for repeated endoscopic assessments of MH as well as a lack of guidance on how to incorporate the various treatment targets into therapeutic decision-making. We aim to review the benefits and challenges of the T2T approach and to discuss potential solutions to further patient care.

2.
Eye (Lond) ; 37(15): 3209-3212, 2023 10.
Article in English | MEDLINE | ID: mdl-36906695

ABSTRACT

PURPOSE: Suspected papilloedema is a frequent cause of referral to paediatric ophthalmology clinics. Recent publications have described a new finding called peripapillary hyperreflective ovoid mass-like structures (PHOMS) that may cause pseudopapilloedema. We evaluated the optical coherence tomography (OCT) scans of the optic nerve in all children referred with suspected papilloedema for the presence of PHOMS and report their frequency. METHODS: The optic nerve OCT scans from children seen in our suspected papilloedema virtual clinic between August 2016 and March 2021 were evaluated for the presence of PHOMS by three assessors. A Fleiss' kappa statistic was calculated to test the agreement between the assessors for the presence of PHOMS. RESULTS: A total of 220 scans from 110 patients were evaluated during the study period. The mean patient age was 11.2 SD ± 3.4, (range 4.1-16.8). PHOMS were identified in at least one eye in 74 (67.3%) patients. Of these, 42 (56.8%) patients had bilateral and 32 (43.2%) had unilateral PHOMS. Excellent agreement between assessors for the presence of PHOMS (Fleiss' kappa 0.9865) was observed. PHOMS were common in association with other identified causes of pseudopapilloedema (81.25%) but were also common in papilloedema (66.67%) and otherwise normal discs (55.36%). CONCLUSIONS: Misdiagnosis of papilloedema can lead to unnecessary and invasive tests. PHOMS are found frequently within the paediatric population referred for suspected disc swelling. They appear to be an independent cause of pseudopapilloedema but are often seen in conjunction with true papilloedema and other causes of pseudopapilloedema.


Subject(s)
Optic Disk , Optic Nerve Diseases , Papilledema , Humans , Child , Papilledema/diagnosis , Papilledema/epidemiology , Prevalence , Optic Nerve Diseases/diagnosis , Optic Nerve Diseases/epidemiology , Tomography, Optical Coherence/methods
3.
Monoclon Antib Immunodiagn Immunother ; 42(2): 65-67, 2023 Apr.
Article in English | MEDLINE | ID: mdl-36787476

ABSTRACT

This study reports on hemodynamic changes observed during monoclonal antibody (mAb) administration for patients with severe acute respiratory distress syndrome-coronavirus-2. Findings from this study may have implications for patient safety. Hemodynamic data from 705 patients who received subcutaneous or intravenous mAb therapy during February 1, 2021-September 30, 2021 in clinics in Arkansas, USA were reviewed. Descriptive statistics and paired t-tests were used to assess blood pressure before and after treatment. Results showed 386 (54.7%) patients experienced a drop in systolic blood pressure (SBP) or diastolic blood pressure (DBP) >5 mmHg. The average drop in SBP was 9.2 mmHg for those patients. Two hundred and eighty-one (39.9%) patients experienced a drop in SBP of >10 mmHg with an average drop in SBP of 12.0 mmHg. The Emergency Use Authorization for mAb does not list hypotension as a contraindication for treatment. Our findings suggest mAb therapy should be administered in an environment where vitals are monitored.


Subject(s)
Antibodies, Monoclonal , COVID-19 , Humans , Blood Pressure , Retrospective Studies , SARS-CoV-2
4.
Health Sci Rep ; 5(2): e543, 2022 Mar.
Article in English | MEDLINE | ID: mdl-35356804

ABSTRACT

Background: Studies comparing the severity of respiratory syncytial virus (RSV) bronchiolitis to other viruses are inconclusive. Our study aimed to compare the severity of bronchiolitis according to the virus. Methods: Data were collected from 1152 infants under one year of age admitted to Children's hospital for Wales, over the winter months of 2014-2020. The cohort was divided based on the virus detected: RSV, RSV with another virus, or other virus. Using t tests and Fisher exact statistical test, the groups were compared based on length of hospital stay, admissions PICU/HDU, intubations, and need of nasogastric (NG) nutritional support. Results: Fifty-six percent throat swabs were RSV positive, 15% had RSV with another virus, and 29% had only another virus. Children positive for RSV had statistically longer hospital admissions and were more likely to need NG nutrition; however, there was no difference between number of PICU/HDU admissions or intubations. The RSV group and RSV with another virus group had no statistical differences.

6.
Infect Dis (Lond) ; 53(7): 486-487, 2021 07.
Article in English | MEDLINE | ID: mdl-33849388
7.
J Gastroenterol Hepatol ; 36(10): 2687-2705, 2021 Oct.
Article in English | MEDLINE | ID: mdl-33638197

ABSTRACT

Reduction in muscle mass is a highly prevalent phenomenon in cirrhosis and is now well-documented to be associated with significant morbidity and mortality. Research into muscle loss in cirrhosis remains limited by an ongoing poor understanding of its relationship with muscle function, physical activity, and aerobic capacity. Alterations in exercise physiology have been documented in studies of individuals with cirrhosis that provide important information on physical function that is not captured by simple quantification of muscle mass. Despite expert consensus recommending regular exercise in end-stage liver disease to maintain muscle mass and function, there is little evidence guiding clinicians as to which form of exercise or delivery mechanism is most effective. It also remains unproven whether any specific intervention can alter clinically relevant outcomes. This review article summarizes the available literature regarding the changes in exercise physiology observed in cirrhosis, the associated impact on physical capacity, and the results of existing trials that examine the potential benefits of exercise delivery in patients with cirrhosis, particularly pertaining to their impact on exercise physiology.


Subject(s)
Exercise Therapy , Liver Cirrhosis , Sarcopenia , Body Composition , Diet Therapy , End Stage Liver Disease/etiology , End Stage Liver Disease/metabolism , End Stage Liver Disease/therapy , Exercise/physiology , Exercise Test , Exercise Therapy/methods , Exercise Tolerance , Frailty/etiology , Frailty/therapy , Humans , Liver Cirrhosis/complications , Liver Cirrhosis/metabolism , Liver Cirrhosis/therapy , Muscle Strength , Quality of Life , Sarcopenia/etiology , Sarcopenia/metabolism , Sarcopenia/therapy
8.
Clin Med (Lond) ; 21(1): e52-e53, 2021 Jan.
Article in English | MEDLINE | ID: mdl-33303623

ABSTRACT

Protective immunity following COVID-19 infection is not yet fully understood. An understanding of COVID-19 reinfection will be key in guiding government and public health policy decisions in the coming months. This report describes two distinct infective episodes of COVID-19 occurring in the same individual, at the time of writing the first published case in the UK. In April 2020 a 25-year-old UK doctor exhibited classical COVID-19 symptoms, including fevers, headaches, and fatigue. A COVID-19 nucleic acid amplification test (NAAT) at the time returned negative. However, a follow-up antibody test in May 2020 returned positive. In October 2020 the same individual exhibited coryzal symptoms and headaches. He was COVID-19 NAAT tested and found to be positive. There was exposure to high viral load prior to reinfection. Overall the second infection was symptomatically milder, with a faster recovery. This evidence for reinfection poses challenges for public health and vaccination efforts to protect against the COVID-19 pandemic.


Subject(s)
Antibodies, Viral/analysis , COVID-19/diagnosis , Pandemics , Reinfection/diagnosis , SARS-CoV-2/immunology , Adult , COVID-19/epidemiology , COVID-19/virology , Humans , Male , Reinfection/epidemiology , Reinfection/virology , United Kingdom/epidemiology
9.
Cancer Treat Res Commun ; 19: 100126, 2019.
Article in English | MEDLINE | ID: mdl-30852467

ABSTRACT

INTRODUCTION: Retrospective studies have evaluated the approach of stereotactic radiotherapy (SRT) to address oligoprogression in patients with EGFR mutant NSCLC on TKI therapy, it has never been prospectively studied. MATERIALS AND METHODS: We treated 25 patients with EGFR mutant NSCLC on erlotinib who had 3 or fewer sites of extra-cranial progression with SRT to progressing sites, followed by re-initiation of erlotinib. RESULTS: Median PFS from the initiation of SRT was 6 months (95% CI 2.5 to 11.6) and median OS was 29 months (95% CI 21.7 to 36.3). Neither baseline nor changes in the Veristrat proteomic predicted PFS. CONCLUSIONS: SRT and TKI continuation may be considered for select patients with EGFR mutant NSCLC and oligo-progression on EGFR TKI therapy.


Subject(s)
Carcinoma, Non-Small-Cell Lung/therapy , Erlotinib Hydrochloride/therapeutic use , Lung Neoplasms/therapy , Protein Kinase Inhibitors/therapeutic use , Radiosurgery/methods , Adult , Aged , Aged, 80 and over , Bone Neoplasms/secondary , Bone Neoplasms/therapy , Brain Neoplasms/secondary , Brain Neoplasms/therapy , Carcinoma, Non-Small-Cell Lung/pathology , Combined Modality Therapy , Disease Progression , ErbB Receptors/antagonists & inhibitors , ErbB Receptors/genetics , Female , Follow-Up Studies , Humans , Liver Neoplasms/secondary , Liver Neoplasms/therapy , Lung Neoplasms/secondary , Lymphatic Metastasis , Male , Middle Aged , Mutation , Prognosis , Survival Rate
10.
Pest Manag Sci ; 73(2): 295-304, 2017 Feb.
Article in English | MEDLINE | ID: mdl-26936226

ABSTRACT

BACKGROUND: In Seychelles, the common myna has been shown to have a negative impact on endangered endemic birds on Denis Island, interfering with breeding attempts and attacking adult endemic birds at their nests. This stimulated an attempt to eradicate the island's mynas. RESULTS: The eradication was undertaken in three phases, overall killing 1186 mynas and lasting 5 years. Decoy trapping was the most effective method for catching mynas, but the last birds were shot. Decoy trapping was compromised by catches of non-target species. Data collection from killed birds indicated that trapping did not favour either sex, and that most breeding occurred during the wetter season, November to March. CONCLUSIONS: Eradication of mynas from small tropical islands is feasible. The Denis Island eradication was prolonged by difficulties in management and staffing. Using volunteers, the cost of the eradication was similar to that of eradicating rodents from the island. In future eradication attempts in Seychelles, possible food stress during the drier season (May to September) might facilitate trapping at this time. Habitat management, especially the removal of short mown grass, could enhance eradication progress. Continued monitoring is needed to confirm eradication and detect any immigration, and also to record responses in the endemic birds. © 2016 Society of Chemical Industry.


Subject(s)
Pest Control/methods , Starlings , Animals , Female , Introduced Species , Male , Reproduction/physiology , Seasons , Seychelles
SELECTION OF CITATIONS
SEARCH DETAIL
...